NCT04208464View on ClinicalTrials.gov

JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 7, 2021

Primary Completion Date

September 25, 2023

Study Completion Date

September 25, 2023

Conditions
Idiopathic Inflammatory Myopathies
Interventions
DRUG

Baricitinib

4mg daily for 24 weeks from baseline

DRUG

Baricitinib

4mg daily for 24 weeks starting after a 12-week treatment delay from baseline

Trial Locations (1)

SE5 9RS

King's College Hospital NHS Foundation Trust, London

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Clinical Trials Unit, Manchester

OTHER

collaborator

Karolinska Institutet

OTHER

lead

University of Manchester

OTHER

NCT04208464 - JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM | Biotech Hunter | Biotech Hunter